TY - JOUR

T1 - Применение препарата альфа-глутамил-триптофан у пациентов с хроническим атрофическим аутоиммунным гастритом: промежуточные результаты

AU - Tryapitsyn, A.V.

AU - Apryatina, V.A.

N1 - Export Date: 05 February 2026; Cited By: 1; Correspondence Address: A.V. Tryapitsyn; Saint Petersburg State University, Saint Petersburg, Russian Federation; email: tryapitsin@gmail.com

PY - 2025

Y1 - 2025

N2 - Objective. To analyze clinical outcomes in patients over 18 years of age receiving alpha-glutamyl-tryptophan for autoimmune atrophic gastritis (AAG). Material and methods. Ten patients diagnosed with chronic AAG were enrolled and prescribed alpha-glutamyl-tryptophan («Rega-stim Gastro», oral gel powder). The study followed a prospective before-and-after design. After two of four planned therapy cours-es, interim results were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and a Likert scale evaluating treatment satisfaction. Adverse events were monitored. Results. Based on the GSRS, four of nine patients reported significant symptom reduction (>10 points), two showed minor improvement (1—2 points), and three had no changes. According to the Likert scale, all patients noted some degree of improve-ment, with five indicating marked relief. One underweight female patient gained weight during therapy. Alpha-glutamyl-trypto-phan had no adverse effect on the efficacy or dosing of concomitant medications. Two patients reported self-limiting diarrhea during the first two days of treatment, and one experienced mild, transient epigastric and periumbilical discomfort during the first five days. These effects resolved without intervention or treatment discontinuation. Conclusion. After two courses of alpha-glutamyl-tryptophan therapy, patients with autoimmune atrophic gastritis demonstrated good treatment tolerability, symptomatic improvement, enhanced quality of life, and no negative interactions with other medications. © 2025, Media Sphera Publishing Group. All rights reserved.

AB - Objective. To analyze clinical outcomes in patients over 18 years of age receiving alpha-glutamyl-tryptophan for autoimmune atrophic gastritis (AAG). Material and methods. Ten patients diagnosed with chronic AAG were enrolled and prescribed alpha-glutamyl-tryptophan («Rega-stim Gastro», oral gel powder). The study followed a prospective before-and-after design. After two of four planned therapy cours-es, interim results were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and a Likert scale evaluating treatment satisfaction. Adverse events were monitored. Results. Based on the GSRS, four of nine patients reported significant symptom reduction (>10 points), two showed minor improvement (1—2 points), and three had no changes. According to the Likert scale, all patients noted some degree of improve-ment, with five indicating marked relief. One underweight female patient gained weight during therapy. Alpha-glutamyl-trypto-phan had no adverse effect on the efficacy or dosing of concomitant medications. Two patients reported self-limiting diarrhea during the first two days of treatment, and one experienced mild, transient epigastric and periumbilical discomfort during the first five days. These effects resolved without intervention or treatment discontinuation. Conclusion. After two courses of alpha-glutamyl-tryptophan therapy, patients with autoimmune atrophic gastritis demonstrated good treatment tolerability, symptomatic improvement, enhanced quality of life, and no negative interactions with other medications. © 2025, Media Sphera Publishing Group. All rights reserved.

KW - alpha-glutamyl-tryptophan

KW - autoimmune atrophic gastritis

KW - drug interaction

KW - dyspeptic symptoms

KW - alpha glutamyl tryptophan

KW - digestive tract agent

KW - unclassified drug

KW - abdominal disease

KW - adult

KW - Article

KW - body weight gain

KW - chronic atrophic autoimmune gastritis

KW - clinical article

KW - clinical assessment

KW - clinical evaluation

KW - controlled study

KW - diarrhea

KW - drug efficacy

KW - drug tolerability

KW - drug use

KW - epigastric discomfort

KW - female

KW - gastritis

KW - gastrointestinal symptom rating scale

KW - groups by age

KW - human

KW - Likert scale

KW - male

KW - patient monitoring

KW - patient satisfaction

KW - patient-reported outcome

KW - periumbilical discomfort

KW - prescription

KW - prospective study

KW - quality of life

KW - sex difference

KW - treatment duration

KW - treatment outcome

KW - underweight

U2 - 10.17116/dokgastro2025140215

DO - 10.17116/dokgastro2025140215

M3 - статья

VL - 14

SP - 5

EP - 11

JO - Доказательная гастроэнтерология

JF - Доказательная гастроэнтерология

SN - 2305-2260

IS - 2

ER -